Appendix 2.
Estimated response rates of the comparators in HEC (Reference efficacy was NEPA from NETU 07–07).
| Complete response | Complete protection | |
|---|---|---|
| OR (95% CI) | OR (95% CI) | |
| Acute phase | ||
| APPAa | 1.498 (0.217–6.385) | 3.501 (1.088–13.263) |
| APR+ONDb | 2.100 (0.432–11.787) | 3.714(1.048–15.364) |
| APR+GRAc | 1.917 (0.298–8.741) | 4.973 (0.829–30.877) |
| APR+5-HT3d | 1.851 (0.674–5.376) | 3.501 (1.088–13.263) |
| OLA+PALe | 0.304 (0.024–2.350) | 1.000 (0.500–1.500) |
| PALf | 3.804 (0.989–17.082) | 5.228 (1.478–21.158) |
| ONDg | 4.112 (0.761–25.003) | 7.389 (1.989–31.627) |
| GRAh | 3.494 (0.663–15.863) | 5.601 (1.265–26.816) |
| 5-HT3i | 3.770 (1.361–11.023) | 5.789 (1.813–21.758) |
| Overall phase | ||
| APPAa | 2.490 (1.103–6.092) | 3.501 (1.088–13.263) |
| APR+ONDb | 1.542 (0.627–3.710) | 3.714 (1.048–15.364) |
| APR+GRAc | 3.068 (1.325–7.448) | 4.973 (0.829–30.877) |
| APR+5-HT3d | 1.817 (1.000–3.401) | 3.501 (1.088–13.263) |
| OLA+PALe | 1.970 (0.637–6.606) | 1.000 (0.500–1.500) |
| PALf | 3.394 (1.579–7.301) | 5.228 (1.478–21.158) |
| ONDg | 3.669 (1.377–9.459) | 7.389 (1.989–31.627) |
| GRAh | 5.714 (2.509–13.397) | 5.601 (1.265–26.816) |
| 5-HT3i | 3.931 (2.152–7.382) | 5.789 (1.813–21.758) |
a
aprepitant+palonosetron+dexamethasone;
b
aprepitant+ondansetron+dexamethasone;
c
aprepitant+granisetron+dexamethasone;
d
aprepitant+5-HT3(pooled)+dexamethasone;
e
olanzapine+palonosetron+dexamethasone;
f
palonosetron+dexamethasone;
g
ondansetron+dexamethasone;
h
granisetron+dexamethasone;
i
5-HT3+dexamethasone;
CI: confidence interval; HEC: highly emetogenic chemotherapy; NEPA: netupitant+palonosetron+dexamethasone; OR: odds ratio.